Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

217
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
217
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

206
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
206
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

453
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
453
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

288
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
288
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

231
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
231
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.5K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Muscle Differentiation in Cultured Pineal Body Cells of Neonatal Rats.

Development, growth & differentiation·2023
Same author

Giant spin polarization and a pair of antiparallel spins in a chiral superconductor.

Nature·2023
Same author

Petahertz non-linear current in a centrosymmetric organic superconductor.

Nature communications·2020
Same author

Long-term outcomes of an extracorporeal irradiated autograft for limb salvage operations in musculoskeletal tumours: over ten years’ observation.

The bone & joint journal·2019
Same author

Correction to: Lower grip strength and dynamic body balance in women with distal radial fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Lower grip strength and dynamic body balance in women with distal radial fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019

Related Experiment Video

Updated: Jan 26, 2026

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection
06:59

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection

Published on: February 2, 2022

4.4K

Low-Dose-Rate and High-Dose-Rate Brachytherapy for Localized Prostate Cancer in ABO-Incompatible Renal Transplant

M Tasaki1, T Kasahara1, M Kaidu2

  • 1Division of Urology, Department of Regenerative & Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

Transplantation Proceedings
|April 14, 2019
PubMed
Summary
This summary is machine-generated.

Brachytherapy (radiation therapy) is safe and effective for prostate cancer patients who have received a kidney transplant. Oncological outcomes were comparable to those without a transplant history.

More Related Videos

Murine Renal Transplantation Procedure
18:48

Murine Renal Transplantation Procedure

Published on: July 10, 2009

30.6K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.8K

Related Experiment Videos

Last Updated: Jan 26, 2026

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection
06:59

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection

Published on: February 2, 2022

4.4K
Murine Renal Transplantation Procedure
18:48

Murine Renal Transplantation Procedure

Published on: July 10, 2009

30.6K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.8K

Area of Science:

  • Urology
  • Oncology
  • Nephrology

Background:

  • Brachytherapy is a standard treatment for localized prostate cancer.
  • Its feasibility in renal transplant recipients (RTRs) remains uncertain.

Purpose of the Study:

  • To evaluate the safety and efficacy of brachytherapy in RTRs with prostate cancer.
  • To compare oncological outcomes between RTRs and non-RTRs.

Main Methods:

  • Retrospective review of 394 prostate cancer patients treated with brachytherapy (LDR or HDR) between 2007-2018.
  • Analysis of clinical data for 3 RTRs who received brachytherapy.

Main Results:

  • All 3 RTRs had stable graft function and received brachytherapy (LDR or HDR).
  • Median follow-up was 44 months.
  • No disease progression or significant adverse events were observed in RTRs.

Conclusions:

  • Low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy are safe and feasible for RTRs with prostate cancer.
  • Oncological outcomes in RTRs appear comparable to non-transplant patients.